The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform

Esther Rincón - One of the best experts on this subject based on the ideXlab platform.

  • TETIS study: evaluation of new topical Hemostatic Agent TT-173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: José López-lópez, Enric Jané-salas, Amparo Santamaría, Beatriz González-navarro, Carlos Arranz-obispo, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans. Methods This is a phase I, randomized, placebo-controlled study to evaluate the efficacy, safety, systemic absorption, and immunogenicity of TT-173 in healthy volunteers undergoing tooth extraction. Subjects received TT-173 or placebo into the alveolar cavity, just after tooth extraction. Time to clot formation, bleeding time, and adverse events were recorded. Results Treatment with TT-173 reduced the bleeding time and the time to clot formation. No adverse events related with product administration were reported. In the same way, neither systemic absorption nor immunogenic reaction against the product was detected. Our findings pave the way to evaluate the usefulness of this new topical Hemostatic Agent in more complex oral surgeries and in those patients affected with coagulation disorders that may compromise the realization of dental procedures. Conclusion The new Hemostatic Agent TT-173 has proven efficacious and safe in healthy subjects undergoing tooth extraction supporting its further evaluation in more complex surgeries. Clinical relevance The development of this new topical Hemostatic Agent could contribute to bleeding control in oral and maxillofacial surgery.

  • tetis study evaluation of new topical Hemostatic Agent tt 173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: Jose Lopezlopez, Amparo Santamaría, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Enric Janesalas, Beatriz Gonzaleznavarro, Carlos Arranzobispo, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans.

Amparo Santamaría - One of the best experts on this subject based on the ideXlab platform.

  • TETIS study: evaluation of new topical Hemostatic Agent TT-173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: José López-lópez, Enric Jané-salas, Amparo Santamaría, Beatriz González-navarro, Carlos Arranz-obispo, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans. Methods This is a phase I, randomized, placebo-controlled study to evaluate the efficacy, safety, systemic absorption, and immunogenicity of TT-173 in healthy volunteers undergoing tooth extraction. Subjects received TT-173 or placebo into the alveolar cavity, just after tooth extraction. Time to clot formation, bleeding time, and adverse events were recorded. Results Treatment with TT-173 reduced the bleeding time and the time to clot formation. No adverse events related with product administration were reported. In the same way, neither systemic absorption nor immunogenic reaction against the product was detected. Our findings pave the way to evaluate the usefulness of this new topical Hemostatic Agent in more complex oral surgeries and in those patients affected with coagulation disorders that may compromise the realization of dental procedures. Conclusion The new Hemostatic Agent TT-173 has proven efficacious and safe in healthy subjects undergoing tooth extraction supporting its further evaluation in more complex surgeries. Clinical relevance The development of this new topical Hemostatic Agent could contribute to bleeding control in oral and maxillofacial surgery.

  • tetis study evaluation of new topical Hemostatic Agent tt 173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: Jose Lopezlopez, Amparo Santamaría, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Enric Janesalas, Beatriz Gonzaleznavarro, Carlos Arranzobispo, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans.

Pilar Sánchez - One of the best experts on this subject based on the ideXlab platform.

  • TETIS study: evaluation of new topical Hemostatic Agent TT-173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: José López-lópez, Enric Jané-salas, Amparo Santamaría, Beatriz González-navarro, Carlos Arranz-obispo, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans. Methods This is a phase I, randomized, placebo-controlled study to evaluate the efficacy, safety, systemic absorption, and immunogenicity of TT-173 in healthy volunteers undergoing tooth extraction. Subjects received TT-173 or placebo into the alveolar cavity, just after tooth extraction. Time to clot formation, bleeding time, and adverse events were recorded. Results Treatment with TT-173 reduced the bleeding time and the time to clot formation. No adverse events related with product administration were reported. In the same way, neither systemic absorption nor immunogenic reaction against the product was detected. Our findings pave the way to evaluate the usefulness of this new topical Hemostatic Agent in more complex oral surgeries and in those patients affected with coagulation disorders that may compromise the realization of dental procedures. Conclusion The new Hemostatic Agent TT-173 has proven efficacious and safe in healthy subjects undergoing tooth extraction supporting its further evaluation in more complex surgeries. Clinical relevance The development of this new topical Hemostatic Agent could contribute to bleeding control in oral and maxillofacial surgery.

  • tetis study evaluation of new topical Hemostatic Agent tt 173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: Jose Lopezlopez, Amparo Santamaría, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Enric Janesalas, Beatriz Gonzaleznavarro, Carlos Arranzobispo, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans.

Ignasi Miquel - One of the best experts on this subject based on the ideXlab platform.

  • TETIS study: evaluation of new topical Hemostatic Agent TT-173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: José López-lópez, Enric Jané-salas, Amparo Santamaría, Beatriz González-navarro, Carlos Arranz-obispo, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans. Methods This is a phase I, randomized, placebo-controlled study to evaluate the efficacy, safety, systemic absorption, and immunogenicity of TT-173 in healthy volunteers undergoing tooth extraction. Subjects received TT-173 or placebo into the alveolar cavity, just after tooth extraction. Time to clot formation, bleeding time, and adverse events were recorded. Results Treatment with TT-173 reduced the bleeding time and the time to clot formation. No adverse events related with product administration were reported. In the same way, neither systemic absorption nor immunogenic reaction against the product was detected. Our findings pave the way to evaluate the usefulness of this new topical Hemostatic Agent in more complex oral surgeries and in those patients affected with coagulation disorders that may compromise the realization of dental procedures. Conclusion The new Hemostatic Agent TT-173 has proven efficacious and safe in healthy subjects undergoing tooth extraction supporting its further evaluation in more complex surgeries. Clinical relevance The development of this new topical Hemostatic Agent could contribute to bleeding control in oral and maxillofacial surgery.

  • tetis study evaluation of new topical Hemostatic Agent tt 173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: Jose Lopezlopez, Amparo Santamaría, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Enric Janesalas, Beatriz Gonzaleznavarro, Carlos Arranzobispo, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans.

Ramón López - One of the best experts on this subject based on the ideXlab platform.

  • TETIS study: evaluation of new topical Hemostatic Agent TT-173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: José López-lópez, Enric Jané-salas, Amparo Santamaría, Beatriz González-navarro, Carlos Arranz-obispo, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans. Methods This is a phase I, randomized, placebo-controlled study to evaluate the efficacy, safety, systemic absorption, and immunogenicity of TT-173 in healthy volunteers undergoing tooth extraction. Subjects received TT-173 or placebo into the alveolar cavity, just after tooth extraction. Time to clot formation, bleeding time, and adverse events were recorded. Results Treatment with TT-173 reduced the bleeding time and the time to clot formation. No adverse events related with product administration were reported. In the same way, neither systemic absorption nor immunogenic reaction against the product was detected. Our findings pave the way to evaluate the usefulness of this new topical Hemostatic Agent in more complex oral surgeries and in those patients affected with coagulation disorders that may compromise the realization of dental procedures. Conclusion The new Hemostatic Agent TT-173 has proven efficacious and safe in healthy subjects undergoing tooth extraction supporting its further evaluation in more complex surgeries. Clinical relevance The development of this new topical Hemostatic Agent could contribute to bleeding control in oral and maxillofacial surgery.

  • tetis study evaluation of new topical Hemostatic Agent tt 173 in tooth extraction
    Clinical Oral Investigations, 2016
    Co-Authors: Jose Lopezlopez, Amparo Santamaría, Ramón López, Ignasi Miquel, Belén Arias, Pilar Sánchez, Enric Janesalas, Beatriz Gonzaleznavarro, Carlos Arranzobispo, Esther Rincón
    Abstract:

    Objectives TT-173 is a new Hemostatic Agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans.